Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses.
Virology
; 566: 106-113, 2022 01.
Article
in English
| MEDLINE | ID: covidwho-1550136
ABSTRACT
BACKGROUND:
Krebs von den Lungen-6 (KL-6) is a molecule that is predominantly expressed by damaged alveolar type II cells, and has been proposed as a marker of COVID-19 and the severity of the disease. Here, we performed a meta-analysis to determine whether KL-6 could be used as a prognostic factor for severe COVID-19.METHODS:
PubMed, Cochrane and Google Scholar were searched until April 20, 2021, and 7 studies were included. KL-6 was considered as the outcome and pooled in meta-analyses.RESULTS:
All included studies compared KL-6 in severe and non-severe patients. Serum KL-6 was higher in severe COVID-19 patients compared to non-severe (n = 6; SMD = 1.25; 95% CI 0.99-1.5; P < 0.001) and healthy controls (n = 4; SMD = 3.07; 95% CI 1.36-4.8; P < 0.001).CONCLUSION:
This data collection revealed the potential clinical significance of KL-6 as a non-expensive predictive biomarker in severe COVID-19 and for the categorization of COVID-19 clinical severity.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Mucin-1
/
SARS-CoV-2
/
COVID-19
Type of study:
Diagnostic study
/
Prognostic study
/
Reviews
/
Systematic review/Meta Analysis
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Virology
Year:
2022
Document Type:
Article
Affiliation country:
J.virol.2021.11.006
Similar
MEDLINE
...
LILACS
LIS